Whether gestational protein restriction affects the reninangiotensin system (RAS) in uterine artery remains unknown. In this study, we hypothesized that gestational protein restriction alters the expression of RAS components in uterine artery. In study one, time-scheduled pregnant Sprague Dawley rats were fed a normal or low-protein (LP) diet from Day 3 of pregnancy until they were killed at Days 19 and 22. The uterine arteries were collected and used for gene expression of Ace, Ace2, Agtr1a, Agtr1b, Agtr2, Esr1, and Esr2 by quantitative real-time PCR and/or Western blotting. LP increased plasma levels of angiotensin II in pregnant rats. In the uterine artery, the expressions of Agtr1a, Agtr1b, and Esr1 were increased by LP at Days 19 and 22 of pregnancy, whereas the abundance of AGTR1 and AGTR2 was increased by LP at Day 19 of pregnancy. The expression of Ace2 was not detectable in rat uterine artery. In study two, virgin female rats were ovariectomized and implanted with either 17beta-estradiol (E2), progesterone (P4), both E2 and P4, or placebo pellets until they were killed 7 days later. In rat uterine artery, E2 and P4 reduced the expression of Agtr1a, and E2 increased the expression of Agtr1b and Agtr2, but neither E2 nor P4 regulated the expression of Ace. These results indicate that gestational protein restriction induces an increase in Agtr1 expression in uterine artery, and thus may exacerbate the vasoconstriction to elevated angiotensin II present in maternal circulation, and that female sex hormones also play a role in this process.
INTRODUCTION
During normal pregnancy, the renin-angiotensin system (RAS) is activated, and its different components demonstrate progressive changes [1] [2] [3] [4] . Besides its critical role in regulating sodium and water homeostasis, RAS, particularly in kidney, has been reported recently to play an important role in fetal programming of hypertension in response to hormonal manipulations [5, 6] ; dietary manipulation, such as maternal global nutrient restriction [7] or protein restriction [8] ; and uteroplacental insufficiency [9] during gestation. Accumulating evidence indicates that RAS in hypertensive offspring affected by intrauterine growth restriction or maternal protein restriction was altered either systemically or locally [9] [10] [11] [12] [13] . However, to date, it is unclear whether and how RAS affects maternal cardiovascular function and metabolism in response to nutritional or hormonal disruption.
Uterine artery remodeling and corresponding uteroplacental blood flow play a critical role in uterine, placental, and fetal growth during pregnancy. Uterine blood flow is a determinant of fetal growth and survival [14] . Maternal vascular remodeling ensures adequate placental perfusion by transforming maternal arteries, including uterine artery, into low-resistance, largecaliber vessels. Physiologically, uterine artery dilation during pregnancy is achieved partly, if not wholly, by increased 17b-estradiol (E2) levels and local nitric oxide production, and reduced vasoactive response to serotonin [15] . Global dietary restriction leads to a remarkable reduction in uterine and placental blood flow [16] , and protein restriction itself impairs vascular relaxation of mesenteric artery in pregnant rats [17] , resulting in fetal growth retardation. In addition, limited studies demonstrate that RAS regulates vasoconstriction in uterine artery. In mice, the contractile response in uterine artery to angiotensin II is elevated in mid and late pregnancy, and vasoconstriction is mainly mediated by angiotensin II receptor, type 1 (AGTR1) and modulated by angiotensin II receptor, type 2 (AGTR2) [18, 19] .
Our laboratory and others have reported that maternal protein restriction, albeit to a different extent in the reduction of protein in diet, causes the development of hypertension in offspring [8, [20] [21] [22] [23] [24] [25] . Although the underlying mechanisms remain unclear, it is known that a low-protein diet alters endocrine status in pregnant rats, including elevated plasma levels of testosterone and estradiol [26] and reduced plasma levels of progesterone [27, 28] . The altered endocrine status may have an impact on maternal RAS function. For instance, estradiol, mainly via estrogen receptor 1 (ESR1), regulates the expression of RAS in a tissue-specific manner, with reduced expression of angiotensin I-converting enzyme (peptidyldipeptidase A) 1 (Ace1) and angiotensin I-converting enzyme (peptidyl-dipeptidase A) 2 (Ace2) in kidney; reduced expression of angiotensin II receptor, type 1a (Agtr1a) in hypothalamus and anterior pituitary; increased expression of Agtr1a and Agtr2 in kidney; and unaltered expression of Ace, Ace2, Agtr1, and Agtr2 in lung [29] [30] [31] [32] [33] . So far, it is unknown whether estrogen regulates expression of RAS in uterine artery; however, the presence and/or function of ESR1 [34] [35] [36] , AGTR1, and AGTR2 [18, 19, 37, 38] in the uterine artery support this possibility.
In this study, we hypothesized that gestational protein restriction and associated changes in female sex hormones may alter the expression of RAS in rat uterine artery. The objectives were to investigate the gene expression of Ace, Ace2, Agtr1a, Agtr1b, Agtr2, Esr1, and estrogen receptor 2 (ER beta; Esr2) in uterine artery in response to gestational protein restriction and to assess whether the expression of these genes is altered by estradiol and progesterone.
All procedures were approved by the Animal Care and Use Committee at the University of Texas Medical Branch and were in accordance with those published by the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (NIH publication no. 85-23, revised 1996) . In study one, timed pregnant Sprague Dawley rats weighing between 175 and 225 g were purchased from Harlan (Houston, TX). At Day 3 of pregnancy, rats were randomly divided into two dietary groups, housed individually, and fed a control (CT; 20% casein) or low-protein (LP; 6% casein) diet until they were killed on Day 19 or 22 of pregnancy (n ¼ 5 rats per diet per day of pregnancy). The isocaloric low-protein and normal-protein diets were purchased from Harlan Teklad (cat. TD.90016 and TD.91352, respectively; Madison, WI). Fetal weights were recorded. The plasma from pregnant rats was collected for angiotensin II enzyme immunoassay. In study two, virgin female rats were ovariectomized, recovered for 5 days, then implanted with either E2 (0.5 mg, 21-day release [OVX þ E2 group]), progesterone (P4; 5 mg, 21-day release [OVX þ P4 group]), both E2 and P4 (OVX þ E2 þ P4 group), or placebo pellets (OVX group; n¼ 5 rats per treatment). All animals were killed 7 days after pellet insertion. The procedures of ovariectomy, hormonal replacement, and efficacy of these procedures were described by Ross et al. [39] . The plasma levels of E2 and P4 in this study were similar to those we reported previously using a similar experimental design [39] .
In both studies, the main uterine artery was separated carefully from surrounding tissues, snap frozen in liquid nitrogen, and stored at À808C until analyzed. The procedures for dissecting the uterine artery were described by Mandala et al. [40] .
Angiotensin II Enzyme Immunoassay
Angiotensin II enzyme immunoassay kit (cat. EK-002-12; Phoenix Pharmaceutical Inc., Burlingame, CA) was used for measuring the concentration of angiotensin II in rat plasma. A total of 50 ll of rat plasma in duplicate was used for this assay. All of the procedures were conducted according to the instructions of the assay kit.
RNA Extraction and RT-PCR
Total RNA from the whole piece of uterine artery (n ¼ 4-5 rats per diet per sex per day of pregnancy) was extracted by Trizol reagent (cat. 15596-018; Invitrogen, Carlsbad, CA), according to the manufacturer's protocol. The possible genomic DNA in total RNAs was digested with RNA-free DNase I (cat. 79254; Qiagen Inc., Valencia, CA), followed by cleanup procedures using a Qiagen RNeasy minikit (cat. 74104; Qiagen). All of these procedures were completed by following the manufacturer's instructions. Complementary DNA (cDNA) was synthesized from 1 lg of total RNA by RT in a total volume of 20 ll by using a MyCycler Thermal Cycler (cat. 170-9703; Bio-Rad Laboratories, Hercules, CA) under the following conditions: one cycle at 288C for 15 min, 428C for 50 min, and 958C for 5 min.
Quantitative Real-Time PCR
Quantitative real-time PCR detection was performed on a CFX96 Real-Time PCR Detection System (cat. 184-5096; Bio-Rad). TaqMan Gene Expression Assays for rat
, and supermix reagents were from Applied Biosystems (Carlsbad, CA). The reaction reagent mixture was incubated at 508C for 2 min, heated to 958C for 10 min, and cycled according to the following parameters: 958C for 30 sec and 608C for 1 min for a total of 40 cycles. Rn18s served as an internal control to standardize the amount of sample RNA added to a reaction. The primers for rat Rn18s are 5 0 -gctgagaagacggtcgaact-3 0 (forward primer) and 5 0 -ttaatgatccttccgcaggt-3 0 (reverse primer). SYBR Green Supermix (cat. 170-8882; Bio-Rad) was used for amplification of Rn18s. The mixture of reaction reagents was incubated at 958C for 10 min and cycled according to the following parameters: 958C for 30 sec and 608C for 1 min for a total of 40 cycles. Negative control without cDNA was performed to test primer specificity. The relative gene expression was calculated by use of the threshold cycle (C T ) Rn18s/C T target gene.
Protein Preparation
Considering the heterogeneity of uterine artery [41] , protein was extracted from the same uterine arteries where the total RNAs were prepared, as described previously [42] . Briefly, proteins were precipitated from organic phase in the RNA preparation procedure. All of the procedures followed the manufacturer's protocol. The final protein pellets were dissolved in resuspension buffer (2% SDS, 10% glycerol, and 50 mM Tris, pH 7.8).
Western Blotting
Aliquots of 20 lg of protein and 43 NuPAGE LDS Sample Buffer (cat. NP0007; Invitrogen) were combined and subjected to electrophoresis with NuPAGE 4-12% Bis-Tris Gel (cat. NP0006; Invitrogen) and MOPS SDS Running Buffer (cat. NP0001; Invitrogen). Briefly, the separated proteins in SDS-PAGE were transferred to a nitrocellulose membrane at 48C overnight. After blocking in 5% nonfat milk, a rabbit anti-ACE1 polyclonal immunoglobulin G (IgG; cat. PT344R; Panora Biotech, Sugarland, TX) at 1:1000 dilution, a goat anti-AGTR1 polyclonal IgG (cat. Sc-31181; Santa Cruz Biotechnology, Santa Cruz, CA), or a rabbit anti-AGTR2 polyclonal IgG (sc-9040; Santa Cruz Biotechnology) at 1:200 dilution was added to a nitrocellulose membrane and incubated at room temperature for 2 h. After washing, the blots were incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (cat. 1030-05; SouthernBiotech, Birmingham, AL) or HRP-conjugated donkey anti-goat IgG (cat. 6420-05; SouthernBiotech) at 1:5000 dilution at room temperature for 1 h. Proteins in blots were visualized with Pierce enhanced chemiluminescence detection (cat. 32209; Thermo Scientific, Rockford, IL) and Blue Lite Autorad Film (cat. F9024; BioExpress, Kaysville, UT) according to the manufacturers' recommendations. Beta-actin (ACTB) was used as an internal control for Western blotting in this study. Primary antibody-mouse monoclonal antibody for ACTB (cat. 3700; Cell Signaling Technology, Danvers, MA)-and secondary antibody-HRPconjugated goat anti-mouse IgG (cat. 1030-05; SouthernBiotech)-were used at 1:10 000 and 1:5000 dilutions, respectively. Visualization of proteins in blots was the same as mentioned above. Blots were incubated with stripping buffer (cat. 46430; Thermo Scientific) at room temperature for 15 min, followed by blocking in 5% nonfat milk for 1 h. The blots were incubated with a rabbit anti-ACE2 polyclonal IgG (cat. ab87436; Abcam Inc., Cambridge, MA) at 1:1000 dilution at room temperature for 2 h. The following procedures were the same as those for ACE analysis.
The signals in films representing the contents of the target proteins ACE, AGTR1, and AGTR2, as well as the internal control protein ACTB, were densitometrically quantified by using Fluorchem 8000 software (Cell Biosciences, Santa Clara, CA). The relative amount of target protein was calculated by the ratio of total densitometrical value of target protein to that of ACTB in each rat uterine artery analyzed by Western blotting.
Statistical Analysis
All quantitative data were subjected to least-squares ANOVA by using the general linear models procedures of the Statistical Analysis System (SAS Institute, Cary, NC). Data on fetal-placental weight, plasma levels of angiotensin II, and gene expression were analyzed for effects of day of pregnancy, diet treatment, and their interaction. Data from steroid hormone supplementation were analyzed using preplanned orthogonal contrasts (OVX þ P4 vs. OVX, OVX þ E2 vs. OVX, and OVX þ P4 þ E2 vs. OVX). A P value GAO ET AL. of 0.05 or less was considered significant, whereas a P value of 0.05 to 0.10 was considered to represent a trend toward significance. Data in tissue weights are presented as means with standard errors, whereas data in gene expression are presented as least-squares means with overall standard errors (SEM).
RESULTS

Fetal Growth Was Impaired by Maternal Protein Restriction
Fetal weights are shown in Figure 1 . Weights of both male and female fetuses in the LP group were lower than those in the CT group at both Days 19 and 22 of pregnancy (P , 0.05).
Plasma Levels of Angiotensin II in Pregnant Rats Were Increased by Maternal Protein Restriction
At Days 19 and 22 of pregnancy, the plasma levels of angiotensin II in the LP group were increased (P , 0.05) by 1.4-fold and 1.5-fold compared with those in the CT group, respectively. In the LP and CT groups, the plasma levels of angiotensin II at Day 22 of pregnancy were increased by 1.9-fold and 2.1-fold, respectively, compared with those at Day 19 of pregnancy (P , 0.05, P , 0.001; Fig. 2 ).
Expression of Ace in Rat Uterine Artery
For the LP group, the mRNA levels of Ace in uterine artery were not changed by Day 19 of pregnancy, but increased 2.3-fold (P , 0.05) by Day 22 of pregnancy (Fig. 3A) , whereas the abundance of ACE protein was decreased by 1.7-fold in the LP group at Day 19 of pregnancy, and not changed by diet at Day 22 of pregnancy (Fig. 3B) . Both Ace2 mRNAs and protein were not detectable in rat uterine artery by quantitative PCR and Western blotting, respectively (data not shown).
Expression of Agtr1a, Agtr1b, Agtr2, Esr1, and Esr2 in Rat Uterine Artery
The mRNA levels of Agtr1a in uterine artery were increased by 3.5-fold (P , 0.001) and 5.0-fold (P , 0.001) in the LP group at Days 19 and 22 of pregnancy, respectively (Fig. 4A) . The expression of Agtr1b in uterine artery was also increased in the LP group by 6.4-fold (P , 0.001) and 3.5-fold (P , 0.001) at Days 19 and 22 of pregnancy, respectively (Fig. 4B) . The abundance of AGTR1 protein in rat uterine artery was increased by 1.7-fold in the LP group compared with the CT 
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group at Day 19 of pregnancy, but not changed by diet at Day 22 of pregnancy (Fig. 4C) .
The mRNA levels of Agtr2 were not changed by diet at both Days 19 and 22 of pregnancy (Fig. 5A) . In contrast, the abundance of AGTR2 in rat uterine artery was increased by 1.5-fold in the LP group compared with the CT group at Day 19 of pregnancy and was not changed at Day 22 of pregnancy (Fig. 5B) .
Expression of Esr1 and Esr2 in Rat Uterine Artery
The expression of Esr1 was increased in the LP group by 2.6-fold (P , 0.001) and 2.1-fold (P , 0.05) at Days 19 and 22 of pregnancy, respectively (Fig. 6A) . The expression of Esr2 was marginally detectable by quantitative PCR, and C T value was in a range of 35.2-38.4 (data not shown).
Expression of Ace, Agtr1a, Agtr1b, and Agt2 in Rat Uterine Artery Was Regulated by Female Sex Hormone
The expression of Ace was not changed by either E2 or P4 (Fig. 7A) . Both E2 and P4 reduced the expression of Agtr1a by 1.4-and 1.9-fold, respectively (P , 0.05, P , 0.001; Fig. 7B) ; E2 increased the expression of Agtr1b by 2.5-fold (P , 0.001 ;  Fig. 7C) ; and E2 increased the expression of Agtr2 by 2.9-fold (P , 0.001; Fig. 7D ).
DISCUSSION
This study, to our knowledge, reports for the first time that gestational protein restriction increases plasma levels of angiotensin II in pregnant dams and alters gene expression of RAS in uterine artery. Numerous studies examined the effects of maternal protein restriction on the RAS of the offspring, as reviewed by Moritz et al. [10] ; however, whether gestational protein restriction affects the expression of RAS components and their functions on the maternal side has been largely ignored. This study shows that gestational protein restriction does affect RAS in pregnant dams and also provides a framework for the investigation of RAS function in response to gestational protein restriction. We suggest that these changes in RAS in response to gestational protein restriction may contribute to reduced vascular relaxation, and thus reduce blood flow to the uteroplacental unit, resulting in fetal growth restriction (Fig. 1) .
Reductions in uterine arterial blood flow can occur through elevated angiotensin II levels in the plasma and/or elevated AGTR1 receptors in the uterine artery. Previous studies in late pregnant ewes have shown a reduction in uterine artery blood flow when plasma angiotensin II levels are elevated [43] . This study demonstrates elevated angiotensin II levels in the plasma for protein-restricted pregnant rats compared with controls. In the CT group, the plasma levels of angiotensin II were 
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increased from Day 19 to Day 22 of pregnancy (Fig. 2) . This is similar to the changes in angiotensin II in human pregnancy [44] . The LP diet did not alter this temporal pattern, but increased the plasma levels of angiotensin II compared with the CT group at both Days 19 and 22 of pregnancy (Fig. 2) . The elevated angiotensin II levels may exacerbate arterial constriction by these following mechanisms: 1) The net bioavailability of angiotensin II for the uterine artery is increased in LP dams, when the elevated levels of circulating angiotensin II overcome the reduction in the local production of angiotensin II in uterine artery due to the decreased abundance of ACE protein by the LP diet (Fig. 3B) . Angiotensin II binds to AGTR1 and finally causes vasoconstriction. 2) Angiotensin II up-regulates the expression of Agtr1 and down-regulates the expression of Agtr2 [45] .
3) The nonexpression of Ace2 in uterine artery (data not shown) makes it impossible to convert angiotensin II to angiotensin (1-7) and reduce the angiotensin II-induced vasoconstriction. 4) In the long term, angiotensin II promotes vascular smooth muscle proliferation via AGTR1 in arteries [3, 46, 47] . As a result, gestational protein restriction may stimulate uterine artery smooth muscle cell proliferation and differentiation.
In the vascular tissue, including uterine artery, AGTR1 and AGTR2 mediate the physiological function of angiotensin II, vasoconstriction or vasodilatation, respectively. Recently, it has been reported that AGTR2 may reduce AGTR1-mediated contractile response to angiotensin II in mouse uterine artery [18] , possibly by stimulating nitric oxide production [48] . During mid and late pregnancy, the vasoconstricting response to angiotensin II, primarily mediated by AGTR1 [49] , is increased in mouse uterine artery, although the AGTR2-mediated vasodilatation is increased as well [48] . Although it is known that the affinities of AGTR1 and AGTR2 to angiotensin II in rat heart are similar [50] , in the uterine artery angiotensin II is suggested to interact primarily with AGTR1 instead of AGTR2 [51] , because the inhibitory effect mediated by AGTR2 on vasoconstriction by AGTR1 is reduced in late pregnancy [52] . In ovine uterine artery, the AGTR1:AGTR2 ratio is increased during pregnancy [53] . This may indicate that AGTR1 may be predominant over AGTR2 in regulating vascular reactivity in the uterine artery. In this study, at Day 19 of pregnancy the abundance of both AGTR1 and AGTR2 proteins was increased by the LP diet (Figs. 4B and 5B), with the unaltered ratio of AGTR1 and AGTR2 in the LP group. Notably, AGTR1 proteins detected by Western blotting in this study contain the products of two genes, Agtr1a and Agtr1b, because the antibody cannot differentiate between the two proteins because of their high identity (95%) [54] . Agtr1a and Agtr1b are different genes, but they show high identity in both nucleotide and amino acid sequences [54] , and their proteins mediate similar vasoconstrictions in response to angiotensin II [55, 56] . It has been reported that protein restriction impairs the vascular relaxation of mesenteric arteries in pregnant rats [17] , and global dietary restriction reduces the uteroplacental blood flow [16] . Thus, it is reasonable to predict that the overall vasoconstriction in the LP uterine artery may be enhanced, and therefore the uterine blood flow is impaired in the LP group. This will be investigated in our future studies.
The expressions of Ace and Agtr2 in uterine artery may be regulated at the posttranscriptional level. The direct evidence in this study is that the protein and mRNA levels of these genes do not match well (Figs. 3 and 5 ). This phenomenon also occurs in these gene expressions in rat placental labyrinth zone [57] . Recently, several studies have demonstrated that gene 
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expressions of RAS components, such as Ace and Agtr2, are posttranscriptionally regulated by microRNAs (miRNAs) [12, 13] . Up-regulation of miRNAs, mmu-MIR27A and mmu-MIR27B by maternal protein restriction reduces the ACE proteins in the brains of offspring [13] . However, to date, the existence of miRNAs regulating the expression of Ace in uterine artery has never been reported. As for the functional significance, the reduction of ACE protein at late pregnancy in response to gestational protein restriction may be an attempt to reduce the local angiotensin II levels, and increased AGTR2 proteins may promote vasodilatation. These may represent a positive adaptation to the maternal protein restriction when fetuses grow rapidly in late pregnancy. The underlying mechanisms warrant further investigation.
The expressions of Agtr1 and Agtr2 are regulated by female sex hormones. Pregnancy demonstrates remarkable changes in hormones, metabolism, and cardiovascular functions. It has been reported that gestational protein restriction increases the maternal plasma levels of estradiol [26] while reducing the plasma levels of progesterone [27, 28] . Accumulating evidence indicates that estrogen regulates gene expression of RAS components in a tissue-specific manner [29] [30] [31] [32] [33] . Estrogen stimulates renal Agtr1a and Agtr2 expression in rodents [29, 30] . In contrast, estrogen down-regulates expression of Agtr1a 
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in hypothalamus [32] . Similarly, in this study we found that the expression of Agtr1a in uterine artery was reduced by both E2 and P4 (Fig. 7B) . It has been reported that gestational protein restriction decreased the plasma levels of P4 in rat [27, 28] ; therefore, the elevated expression of Agtr1a in response to gestational protein restriction may be caused partly by the reduced levels of P4 [27, 28] , because angiotensin II also stimulates the expression of Agtr1 [45] . This study also demonstrates that estrogen increases the expression of Agtr1b and Agtr2 in rat uterine artery (Fig. 7, C and D) . Further, the expression of Esr1 in the uterine artery was elevated in proteinrestricted pregnant rats (Fig. 6) . Thus, elevated expression of Esr1 and plasma levels of estrogen in protein-restricted mothers could have contributed to the increased expressions of Agtr1b in uterine artery. As a result, although estrogen is a potent vasodilator and critical for the cardiovascular adaption to pregnancy, estrogen-induced RAS changes in the uterine artery in response to gestational protein restriction failed to restore normal vasoactivity, as shown by the impaired vascular relaxation [17] .
In summary, this study reveals that gestational protein restriction increases the maternal plasma levels of angiotensin II and Agtr1 expression in uterine artery, and thus may exacerbate the vasoconstriction in uterine artery, and that female sex hormones also play a role in this process. In future studies, the following relevant questions will be addressed: 1) Is the vasoconstricting response of uterine artery to angiotensin II elevated in rats with gestational protein restriction? 2) Which type of angiotensin II receptors play predominant roles in the vasoconstriction of uterine artery in vivo or ex vivo? 3) Can the altered expression of RAS by gestational protein restriction be reversed by supplementation or blockage of sex hormones? These answers will provide valuable information for the role of altered RAS in fetal programming on adulthood hypertension in response to nutritional disruptions.
